Jia et al. reported that DANCR knockdown reduces the enzalutamide-induced invasion and migration of PC cells and that targeting DANCR may be promising for preventing prostate cancer metastasis and mitigating potential side effects of AR inhibitors. Here, DANCR is linked to pachyonychia congenita.